AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 19674695 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (experimental and control)
Number of subjects: 13
Study 15960063 — intervention group
Group type: EXPERIMENTAL
Intervention: APN prenatal care delivered in women's homes
Number of subjects: 83
Study 12071338 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin treatment in untreated type 1 patients
Number of subjects: 298
Study 12071338 — intervention group
Group type: COMPARATOR
Intervention: Untreated type 1 patients
Number of subjects: 298
Study 12071338 — intervention group
Group type: EXPERIMENTAL
Intervention: Insulin therapy adjustment in males aged 16-59 years
Number of subjects: 298
Study 12071338 — intervention group
Group type: COMPARATOR
Intervention: Insulin therapy in women with insufficient glucose control
Number of subjects: 298
Study 12071338 — intervention group
Group type: COMPARATOR
Intervention: Type 2 diabetic patients (men over 40 years)
Number of subjects: 298
Study 12071338 — intervention group
Group type: EXPERIMENTAL
Intervention: Type 2 diabetic patients (women)
Number of subjects: 298
Study 10721060 — intervention group
Group type: EXPERIMENTAL
Intervention: Indole-3-pyruvic acid (IPA)
Number of subjects: 0
Study 7735265 — intervention group
Group type: EXPERIMENTAL
Intervention: Acebutolol (400 mg/day)
Number of subjects: 12
Study 7735265 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 12
Study 1755249 — intervention group
Group type: EXPERIMENTAL
Intervention: Subhepatic drainage
Number of subjects: 56
Study 1755249 — intervention group
Group type: COMPARATOR
Intervention: No subhepatic drainage (Control)
Number of subjects: 56
Study 6620013 — intervention group
Group type: EXPERIMENTAL
Intervention: Chest physical therapy (CPT) administered by a parent, regular twice daily basis
Number of subjects: 8
Study 31088511 — intervention group
Group type: EXPERIMENTAL
Intervention: Strong electroacupuncture (EA) (> 2 mA)
Number of subjects: 301
Study 31088511 — intervention group
Group type: EXPERIMENTAL
Intervention: Weak electroacupuncture (EA) (< 0.5 mA)
Number of subjects: 301
Study 31088511 — intervention group
Group type: COMPARATOR
Intervention: Sham electroacupuncture (non-acupoint)
Number of subjects: 301
Study 30526648 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 32 mg
Number of subjects: 90
Study 30526648 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 64 mg
Number of subjects: 90
Study 30526648 — intervention group
Group type: EXPERIMENTAL
Intervention: Buprenorphine 96 mg
Number of subjects: 90
Study 30526648 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 90
Study 26820776 — intervention group
Group type: EXPERIMENTAL
Intervention: Health-based messages
Number of subjects: 0
Study 26820776 — intervention group
Group type: EXPERIMENTAL
Intervention: Descriptive social norm-based messages
Number of subjects: 0
Study 26820776 — intervention group
Group type: COMPARATOR
Intervention: Control condition messages
Number of subjects: 0
Study 24726614 — intervention group
Group type: EXPERIMENTAL
Intervention: Platinum-based regimens
Number of subjects: 534
Study 24726614 — intervention group
Group type: EXPERIMENTAL
Intervention: Parametric survival model
Number of subjects: 534
Study 24726614 — intervention group
Group type: EXPERIMENTAL
Intervention: Simulations
Number of subjects: 534
Study 22016358 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet + CoQ (Med + CoQ)
Number of subjects: 20
Study 22016358 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med)
Number of subjects: 20
Study 22016358 — intervention group
Group type: COMPARATOR
Intervention: Saturated fatty acid‐rich diet (SFA)
Number of subjects: 20
Study 19160389 — intervention group
Group type: EXPERIMENTAL
Intervention: Persistent allergic rhinitis patients (PER)
Number of subjects: 49
Study 19160389 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate/severe PER patients with SRH
Number of subjects: 49
Study 19160389 — intervention group
Group type: EXPERIMENTAL
Intervention: Nasal nitric oxide (nNO) levels in PER patients
Number of subjects: 49
Study 19160389 — intervention group
Group type: COMPARATOR
Intervention: Healthy controls
Number of subjects: 49
Study 18372697 — intervention group
Group type: EXPERIMENTAL
Intervention: Exercise (EX) - treadmill running 3-4 days per week for 40-min followed by 10-min of static LBNP, and resistive exercise on a flywheel device every 3rd day
Number of subjects: 24
Study 18372697 — intervention group
Group type: COMPARATOR
Intervention: Control group (non-exercisers)
Number of subjects: 24
Study 18372697 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitroglycerin (0.3 mg sublingual administration)
Number of subjects: 24
Study 15902411 — intervention group
Group type: EXPERIMENTAL
Intervention: General Health Questionnaire (GHQ)
Number of subjects: 7357
Study 15902411 — intervention group
Group type: COMPARATOR
Intervention: Revised Clinical Interview Schedule (CIS-R)
Number of subjects: 7357
Study 11774111 — intervention group
Group type: EXPERIMENTAL
Intervention: Vitamin E hemodialyzer (CL‐EE)
Number of subjects: 10
Study 11774111 — intervention group
Group type: COMPARATOR
Intervention: Control dialyzer
Number of subjects: 10
Study 9702435 — intervention group
Group type: EXPERIMENTAL
Intervention: Orlistat 120 mg three times a day with a mildly hypocaloric diet
Number of subjects: 391
Study 9702435 — intervention group
Group type: COMPARATOR
Intervention: Placebo with a mildly hypocaloric diet
Number of subjects: 391
Study 8026408 — intervention group
Group type: EXPERIMENTAL
Intervention: High VNS
Number of subjects: 67
Study 8026408 — intervention group
Group type: COMPARATOR
Intervention: Low VNS
Number of subjects: 67
Study 3377953 — intervention group
Group type: EXPERIMENTAL
Intervention: Positive suggestions
Number of subjects: 0
Study 3377953 — intervention group
Group type: EXPERIMENTAL
Intervention: Nonsense suggestions
Number of subjects: 0
Study 3377953 — intervention group
Group type: EXPERIMENTAL
Intervention: Seaside sounds
Number of subjects: 0
Study 3377953 — intervention group
Group type: EXPERIMENTAL
Intervention: Sounds from the operating theatre
Number of subjects: 0
Study 31969443 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB) with ropivacaine 0.5% and epinephrine (20 mL unilateral or 16 mL/side for bilateral)
Number of subjects: 100
Study 31969443 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral nerve block (PVB) with ropivacaine 0.5% and epinephrine (20 mL unilateral or 16 mL/side for bilateral)
Number of subjects: 100
Study 31969443 — intervention group
Group type: EXPERIMENTAL
Intervention: Erector spinae plane block (ESPB)
Number of subjects: 100
Study 31969443 — intervention group
Group type: COMPARATOR
Intervention: Paravertebral nerve block (PVB)
Number of subjects: 100
Study 31374368 — intervention group
Group type: EXPERIMENTAL
Intervention: 8-week home-based physical activity intervention (twice weekly supervised resistance training and unsupervised walking program)
Number of subjects: 14
Study 31374368 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 14
Study 28793991 — intervention group
Group type: EXPERIMENTAL
Intervention: Ready-to-use supplemental food (RUSF)
Number of subjects: 1828
Study 28793991 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy blend with UNIMMAP (CSB+)
Number of subjects: 1828
Study 28793991 — intervention group
Group type: COMPARATOR
Intervention: Corn-soy blend with iron and folic acid (CSB+)
Number of subjects: 1828
Study 25730522 — intervention group
Group type: EXPERIMENTAL
Intervention: Brief motivational intervention
Number of subjects: 1040
Study 25730522 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol Edu for Sanctions
Number of subjects: 1040
Study 25730522 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol 101 Plus
Number of subjects: 1040
Study 25730522 — intervention group
Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 1040
Study 22662393 — intervention group
Group type: COMPARATOR
Intervention: Enhanced Cued Recall Test - Computer-based
Number of subjects: 77
Study 22662393 — intervention group
Group type: COMPARATOR
Intervention: Line Orientation Test - Computer-based
Number of subjects: 77
Study 22662393 — intervention group
Group type: EXPERIMENTAL
Intervention: Paper-and-pencil tests
Number of subjects: 77
Study 22662393 — intervention group
Group type: EXPERIMENTAL
Intervention: Total score difference between modalities
Number of subjects: 77
Study 22662393 — intervention group
Group type: EXPERIMENTAL
Intervention: Computer-based tests
Number of subjects: 77
Study 20528005 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol 2000 mg twice daily with standard breakfast
Number of subjects: 8
Study 20528005 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol 2000 mg twice daily with high-fat breakfast
Number of subjects: 8
Study 20528005 — intervention group
Group type: COMPARATOR
Intervention: Quercetin 500 mg twice daily
Number of subjects: 8
Study 20528005 — intervention group
Group type: COMPARATOR
Intervention: 5% alcohol 100 mL
Number of subjects: 8
Study 20528005 — intervention group
Group type: EXPERIMENTAL
Intervention: Trans-resveratrol 2000 mg twice daily
Number of subjects: 8
Study 18579903 — intervention group
Group type: EXPERIMENTAL
Intervention: 0 kg load (body mass only)
Number of subjects: 18
Study 18579903 — intervention group
Group type: COMPARATOR
Intervention: 20 kg load
Number of subjects: 18
Study 18579903 — intervention group
Group type: COMPARATOR
Intervention: 40 kg load
Number of subjects: 18
Study 18579903 — intervention group
Group type: COMPARATOR
Intervention: 60 kg load
Number of subjects: 18
Study 18579903 — intervention group
Group type: COMPARATOR
Intervention: 80 kg load
Number of subjects: 18
Study 16156492 — intervention group
Group type: EXPERIMENTAL
Intervention: Solution Focused Brief Therapy (SFBT)
Number of subjects: 55
Study 16156492 — intervention group
Group type: EXPERIMENTAL
Intervention: Common Factors Therapy (CFT)
Number of subjects: 55
Study 16156492 — intervention group
Group type: COMPARATOR
Intervention: Waiting List Control (WC)
Number of subjects: 55
Study 11950019 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based exercise intervention package (exercise/information video, exercise progress chart, patient education booklet, AS exercise reminder stickers)
Number of subjects: 200
Study 11950019 — intervention group
Group type: EXPERIMENTAL
Intervention: Home based exercise intervention package
Number of subjects: 200
Study 11950019 — intervention group
Group type: COMPARATOR
Intervention: Control group (follow-up)
Number of subjects: 200
Study 10429566 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride baths
Number of subjects: 73
Study 10429566 — intervention group
Group type: COMPARATOR
Intervention: Common water baths
Number of subjects: 73
Study 7772424 — intervention group
Group type: EXPERIMENTAL
Intervention: Ephedrine 0.6 mg kg‐1 body weight
Number of subjects: 98
Study 7772424 — intervention group
Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 98
Study 2185693 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B syrup 2,400 mg/day
Number of subjects: 36
Study 2185693 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B syrup 1,200 mg/day
Number of subjects: 36
Study 2185693 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B syrup 800 mg/day
Number of subjects: 36
Study 2185693 — intervention group
Group type: EXPERIMENTAL
Intervention: Amphotericin B syrup 400 mg/day
Number of subjects: 36
Study 7444371 — intervention group
Group type: EXPERIMENTAL
Intervention: Hog mucosa heparin
Number of subjects: 129
Study 7444371 — intervention group
Group type: EXPERIMENTAL
Intervention: Beef lung heparin
Number of subjects: 129
Study 7444371 — intervention group
Group type: COMPARATOR
Intervention: Control group (no specific control mentioned)
Number of subjects: 129
Study 30112721 — intervention group
Group type: EXPERIMENTAL
Intervention: Stent placement
Number of subjects: 28
Study 29523095 — intervention group
Group type: EXPERIMENTAL
Intervention: Health literacy (measured by Newest Vital Sign - NVS)
Number of subjects: 247
Study 29523095 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient activation (measured by Patient Activation Measure-13 - PAM-13)
Number of subjects: 247
Study 26795764 — intervention group
Group type: EXPERIMENTAL
Intervention: Contralateral manual acupuncture (n=38) for 4 weeks
Number of subjects: 80
Study 26795764 — intervention group
Group type: COMPARATOR
Intervention: Waiting list group receiving conventional orthopaedic therapy (n=42)
Number of subjects: 80
Study 24907444 — intervention group
Group type: EXPERIMENTAL
Intervention: Altis Single Incision Sling System
Number of subjects: 113
Study 22558370 — intervention group
Group type: EXPERIMENTAL
Intervention: 30-minute sessions of biofeedback‐assisted stress management training (SMT) while immersed in a horror/first‐person shooter game for three days
Number of subjects: 41
Study 22558370 — intervention group
Group type: COMPARATOR
Intervention: No additional stress management training (SMT) for three days
Number of subjects: 41
Study 20671098 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of drug therapy combined with behavioral intervention (pelvic‐floor muscle exercises, UI prevention strategies, delayed voiding)
Number of subjects: 307
Study 20671098 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 weeks of drug therapy combined with behavioral intervention
Number of subjects: 307
Study 20671098 — intervention group
Group type: COMPARATOR
Intervention: 10 weeks of drug therapy only
Number of subjects: 307
Study 18313371 — intervention group
Group type: EXPERIMENTAL
Intervention: 7.5 mg zopiclone (test)
Number of subjects: 16
Study 18313371 — intervention group
Group type: COMPARATOR
Intervention: 7.5 mg zopiclone (reference)
Number of subjects: 16
Study 15801925 — intervention group
Group type: EXPERIMENTAL
Intervention: Micafungin (150 mg/day)
Number of subjects: 523
Study 15801925 — intervention group
Group type: COMPARATOR
Intervention: Fluconazole (200 mg/day)
Number of subjects: 523
Study 12093836 — intervention group
Group type: EXPERIMENTAL
Intervention: Ultrasound-guided embryo transfer
Number of subjects: 515
Study 12093836 — intervention group
Group type: COMPARATOR
Intervention: Clinical touch embryo transfer
Number of subjects: 515
Study 10511329 — intervention group
Group type: EXPERIMENTAL
Intervention: 1800 IU/d of ergocalciferol (vitamin D2)
Number of subjects: 18
Study 10511329 — intervention group
Group type: COMPARATOR
Intervention: Control group (n=7)
Number of subjects: 18
Study 7742708 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 atm abs oxygen (HBO)
Number of subjects: 8
Study 7742708 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 atm abs O2 with 190 mmHg inspired PCO2 (hypercapnia)
Number of subjects: 8
Study 7742708 — intervention group
Group type: COMPARATOR
Intervention: Air at atmospheric pressure (Control)
Number of subjects: 8
Study 2127324 — intervention group
Group type: EXPERIMENTAL
Intervention: Clinical pharmacokinetic service
Number of subjects: 75
Study 7194733 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide (CYC)
Number of subjects: 32
Study 7194733 — intervention group
Group type: COMPARATOR
Intervention: Cyclophosphamide, methotrexate, and fluorouracil (CMF)
Number of subjects: 32
Study 30252571 — intervention group
Group type: EXPERIMENTAL
Intervention: One-quarter standard-dose ticagrelor
Number of subjects: 60
Study 30252571 — intervention group
Group type: EXPERIMENTAL
Intervention: Half standard-dose ticagrelor
Number of subjects: 60
Study 30252571 — intervention group
Group type: EXPERIMENTAL
Intervention: Standard-dose ticagrelor
Number of subjects: 60
Study 30252571 — intervention group
Group type: COMPARATOR
Intervention: Clopidogrel (control)
Number of subjects: 60
Study 30252571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ticagrelor groups (all doses)
Number of subjects: 60
Study 30252571 — intervention group
Group type: EXPERIMENTAL
Intervention: Half and standard-dose ticagrelor
Number of subjects: 60
Study 27762434 — intervention group
Group type: EXPERIMENTAL
Intervention: Oxycodone-naloxone
Number of subjects: 62
Study 27762434 — intervention group
Group type: COMPARATOR
Intervention: Oxycodone
Number of subjects: 62
Study 25963981 — intervention group
Group type: EXPERIMENTAL
Intervention: Dihydroartemisinin-piperaquine (DHA-PQ)
Number of subjects: 65
Study 25963981 — intervention group
Group type: COMPARATOR
Intervention: Sulfadoxine-pyrimethamine-piperaquine (SP-PQ)
Number of subjects: 65
Study 24411682 — intervention group
Group type: EXPERIMENTAL
Intervention: Continuous, inhibiting TBS (cTBS) to the right dlPFC
Number of subjects: 32
Study 24411682 — intervention group
Group type: COMPARATOR
Intervention: Bilateral sham stimulation
Number of subjects: 32
Study 21104484 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-hypnosis training (HYP)
Number of subjects: 15
Study 21104484 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive restructuring (CR)
Number of subjects: 15
Study 21104484 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined hypnosis-cognitive restructuring intervention (CR-HYP)
Number of subjects: 15
Study 21104484 — intervention group
Group type: COMPARATOR
Intervention: Education control intervention
Number of subjects: 15
Study 19202426 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 gauge vitrectomy
Number of subjects: 90
Study 19202426 — intervention group
Group type: EXPERIMENTAL
Intervention: 23 gauge vitrectomy
Number of subjects: 90
Study 19202426 — intervention group
Group type: EXPERIMENTAL
Intervention: 25 gauge vitrectomy
Number of subjects: 90
Study 18499625 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 1200 mg
Number of subjects: 86
Study 18499625 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 86
Study 16148323 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interview (Schedule for Affective Disorders and Schizophrenia for School‐aged Children‐Present and Lifetime Versions) administered by a trained interviewer before the initial physician visit
Number of subjects: 225
Study 16148323 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured interview (Schedule for Affective Disorders and Schizophrenia for School‐aged Children‐Present and Lifetime Versions)
Number of subjects: 225
Study 16148323 — intervention group
Group type: COMPARATOR
Intervention: Assessment as usual
Number of subjects: 225
Study 12133120 — intervention group
Group type: EXPERIMENTAL
Intervention: Nimodipine and dextropropoxiphen (experimental group)
Number of subjects: 80
Study 12133120 — intervention group
Group type: COMPARATOR
Intervention: Dextropropoxiphen and benzodiazepine (control group 1)
Number of subjects: 80
Study 12133120 — intervention group
Group type: COMPARATOR
Intervention: Alpha-2-adrenergic agents and naltrexone (control group 2)
Number of subjects: 80
Study 9918565 — intervention group
Group type: EXPERIMENTAL
Intervention: Dextromethorphan (50 mg DEM hydrobromide orally)
Number of subjects: 7
Study 9918565 — intervention group
Group type: COMPARATOR
Intervention: Quinidine (50 mg Qd sulfate orally)
Number of subjects: 7
Study 9918565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 7
Study 8589013 — intervention group
Group type: EXPERIMENTAL
Intervention: Routine blood tests (alkaline phosphatase, SGOT, gamma-GT, bilirubin, serum calcium, serum creatinine)
Number of subjects: 4105
Study 8589013 — intervention group
Group type: EXPERIMENTAL
Intervention: Alkaline phosphatase
Number of subjects: 4105
Study 8589013 — intervention group
Group type: EXPERIMENTAL
Intervention: Other routine blood tests (bilirubin, serum calcium, serum creatinine)
Number of subjects: 4105
Study 2224916 — intervention group
Group type: EXPERIMENTAL
Intervention: Etretinate 25 mg daily
Number of subjects: 0
Study 2224916 — intervention group
Group type: COMPARATOR
Intervention: Identical placebo
Number of subjects: 0
Study 343678 — intervention group
Group type: EXPERIMENTAL
Intervention: Hepatitis B immune globulin (HBIG)
Number of subjects: 0
Study 343678 — intervention group
Group type: COMPARATOR
Intervention: Immune serum globulin (ISG)
Number of subjects: 0
Study 31648203 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-intensity stretching
Number of subjects: 14
Study 31648203 — intervention group
Group type: EXPERIMENTAL
Intervention: High-intensity stretching
Number of subjects: 14
Study 31004432 — intervention group
Group type: EXPERIMENTAL
Intervention: Investigational therapeutics for Ebola patients
Number of subjects: 0
Study 31004432 — intervention group
Group type: EXPERIMENTAL
Intervention: Surveillance for Zika and related viruses
Number of subjects: 0
Study 31004432 — intervention group
Group type: EXPERIMENTAL
Intervention: Online health assessment survey for U.S. Marines
Number of subjects: 0
Study 31004432 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidrug-Resistant and Virulent Organisms Trauma Infections Initiative
Number of subjects: 0
Study 31004432 — intervention group
Group type: EXPERIMENTAL
Intervention: Antimicrobial Resistance and Stewardship Collaborative Clinical Research Consortium
Number of subjects: 0
Study 28392272 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model based on preprocedural risk factors (age, serum creatinine levels, N-terminal pro b-type natriuretic peptide levels, high-sensitivity C-reactive protein, and primary PCI)
Number of subjects: 1777
Study 28392272 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model developed from the developmental data set (n=1076)
Number of subjects: 1777
Study 28392272 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model validated in the validation data set (n=701)
Number of subjects: 1777
Study 28392272 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model (0-36 scale)
Number of subjects: 1777
Study 28392272 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk score model
Number of subjects: 1777
Study 26357943 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive behaviour therapy-informed software application (Actissist) plus Treatment As Usual (TAU)
Number of subjects: 36
Study 26357943 — intervention group
Group type: COMPARATOR
Intervention: Symptom monitoring software application (ClinTouch) plus Treatment As Usual (TAU)
Number of subjects: 36
Study 23826104 — intervention group
Group type: EXPERIMENTAL
Intervention: 800 IU ergocalciferol daily until delivery
Number of subjects: 180
Study 23826104 — intervention group
Group type: EXPERIMENTAL
Intervention: Single oral bolus of 200,000 IU cholecalciferol
Number of subjects: 180
Study 23826104 — intervention group
Group type: EXPERIMENTAL
Intervention: Any vitamin D (both supplementation groups combined)
Number of subjects: 180
Study 23826104 — intervention group
Group type: COMPARATOR
Intervention: No vitamin D (control group)
Number of subjects: 180
Study 23826104 — intervention group
Group type: EXPERIMENTAL
Intervention: Atopy (assessed by skin test, serum IgE, exhaled nitric oxide, impulse oscillometry)
Number of subjects: 180